TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

IPSEN

OncologyGastroenterologyNeurology
Pharma

IPSEN is a pharmaceutical company focused on Oncology, Gastroenterology, Neurology. Key products include BYLVAY.

2005
Since
5
Drugs
-
Trials
7
Approved (2yr)

Key Drugs

BYLVAY
odevixibat
IBAT 3 indications · 2021
ONIVYDE
irinotecan hydrochloride
Oncology
Topoisomerase 1 1 indications · 2015
SOHONOS
palovarotene
RARγ 1 indications · 2023
IQIRVO
elafibranor
PPAR-alpha 1 indications · 2024

Recent Activity

BYLVAY 2025-12-19
Efficacy
INCRELEX 2025-07-09
Labeling
BYLVAY 2025-03-20
Labeling
SOHONOS 2025-03-13
Efficacy
ONIVYDE 2024-12-23
Labeling
IQIRVO 2024-06-10
Type 1 - New Molecular Entity
INCRELEX 2024-03-15
Efficacy
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 67%
1 drugs Phase 3: 6 Phase 2: 5 Phase 1: 10
Gastroenterology 20%
1 drugs Phase 3: 1 Phase 2: 1 Phase 1: 3
Neurology 13%
0 drugs Phase 3: 2 Phase 2: 1

Pipeline Strength Pro

Loading...

Competitors Pro

Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology, Neurology
Takeda big-pharma
Oncology, Gastroenterology, Neurology
Pfizer big-pharma
Oncology, Gastroenterology
Amgen biotech
Oncology, Gastroenterology, Neurology
EMD SERONO INC biotech
Oncology, Neurology, Gastroenterology